Pharmacological and structural characterization of vibostolimab, a novel anti-TIGIT blocking antibody for cancer immunotherapy
Vibostolimab is a novel anti-TIGIT antibody that completely blocks CD155 binding and induces T-cell activation. From experiments using a mouse tumor model and mouse surrogate anti-TIGIT antibody, we demonstrate direct evidence where it not only activates cytotoxic T cells but also induces the activation of antigen-presenting cells. The clinical relevance of vibostolimab, based on these mechanisms, in combination with pembrolizumab was recently tested in registrational trials.
Authors
- Tanya E. Keenan (ORCID: https://orcid.org/0000-0001-5300-9998)
- Laurence Fayadat‐Dilman (ORCID: https://orcid.org/0000-0001-6285-8924)
- Mingmei Cai
- Eunseon Ahn (ORCID: https://orcid.org/0000-0001-9749-477X)
- Mark Hsieh
- Jing Yuan (ORCID: https://orcid.org/0000-0002-8907-9143)
- Ellen Y. T. Chien (ORCID: https://orcid.org/0009-0002-1731-5431)
- Hongmei Wang (ORCID: https://orcid.org/0000-0002-5881-2488)
- Wolfgang Seghezzi
- Mark A. McCoy (ORCID: https://orcid.org/0000-0003-3994-6605)
- Daniel Malashock (ORCID: https://orcid.org/0000-0002-7454-2211)
- Janica C. Wong (ORCID: https://orcid.org/0000-0001-5513-1487)
- Thierry Fischmann (ORCID: https://orcid.org/0000-0003-3406-3061)
- Douglas C. Wilson (ORCID: https://orcid.org/0009-0007-6893-5434)
- Srishti Chakravorty (ORCID: https://orcid.org/0000-0002-6745-9129)
- Todd Mayhood
- Jeanne Baker
- Maribel Beaumont
- David Ban (ORCID: https://orcid.org/0000-0002-3153-3104)
- Wendy M. Blumenschein (ORCID: https://orcid.org/0009-0007-1175-9361)
- Soheila Bahmanjah
- Sybil M. Genther Williams
- Jin‐Hwan Han (ORCID: https://orcid.org/0000-0003-2442-8442)
- Jeffery Grein
- Komal Pradhan (ORCID: https://orcid.org/0009-0007-2267-7505)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Quantitative BioSciences (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-008972
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59